Menopause Treatment: A Doctor's Guide for 2026

What menopause treatment actually treats

Menopause is a point in time rather than a process: a woman has reached it after 12 consecutive months without a period [5]. The years before that are the menopausal transition, or perimenopause, which usually begins in the 40s and averages about four years, though it can run up to 10 [5]. Pregnancy is still possible during perimenopause [5]. In the US the average age of menopause is 52, and most women reach it between 45 and 55 [5][6].

STRAW+10, the standard staging system, is built around the final menstrual period [13]. Early transition is persistent cycle variability — a difference of 7 or more days between consecutive cycle lengths, recurring within 10 cycles; late transition is 60 days or more without a period; the final period is confirmed only once 12 months have passed [14]. A random FSH above 25 IU/L is a marker for late transition only, and AMH, inhibin B and antral follicle count are supportive rather than diagnostic because the assays are not standardized [14]. Menopause is defined by the bleeding history, not by a hormone level.

Hot flashes last longer than most people expect. In SWAN, a study of 3,302 women at seven US sites, the median total duration of frequent hot flashes and night sweats was 7.4 years, and the median persistence after the final menstrual period was 4.5 years; women who first reported frequent hot flashes or night sweats before menopause or in early perimenopause had the longest median duration, more than 11.8 years [15].

Hormone therapy: where the evidence is strongest

The Menopause Society's 2022 position statement calls hormone therapy the most effective treatment for vasomotor symptoms and for genitourinary syndrome of menopause, and states that it prevents bone loss and fracture [1]. For women younger than 60 or within 10 years of menopause onset with no contraindications, the benefit-risk ratio is favorable for bothersome symptoms and for prevention of bone loss; for women starting more than 10 years after menopause or after age 60, the ratio appears less favorable because the absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia are higher [1]. Risks differ by type, dose, duration, route, timing of initiation and whether a progestogen is used [1].

What that means in products: estrogen alone — oral conjugated estrogens, oral estradiol, patches, gels, spray — for women without a uterus, and estrogen plus a progestogen for women with one, since unopposed estrogen raises endometrial cancer risk and adding a progestin reduces endometrial hyperplasia [10]. Progesterone capsules (Prometrium) are labeled for endometrial protection in women with a uterus who take conjugated estrogens [16]. Conjugated estrogens with bazedoxifene (Duavee) pairs estrogen with an estrogen agonist/antagonist instead of a progestin, and is for women with a uterus, for vasomotor symptoms and osteoporosis prevention [17].

The estrogen labels give the starting point for hot flashes: the Premarin label says to treat with the lowest effective dose, generally starting at 0.3 mg daily, with periodic reassessment [10]. The Divigel label, updated in February 2026, adds that initiation should be considered in women under 60 or within 10 years of menopause onset [18].

What changed in the labels, and what did not

On 10 November 2025 the FDA asked companies that hold menopausal hormone therapy applications to change their labels: remove the cardiovascular disease, breast cancer and probable dementia statements from the boxed warning, remove the boxed recommendation to use the lowest effective dose for the shortest time, and remove the probable dementia warning from labeling — while keeping the endometrial cancer boxed warning for systemic estrogen-alone products [19][20]. For systemic products, the cardiovascular and breast cancer warnings stay in the Warnings and Precautions section, and the labels are to add WHI data for women aged 50 to 59 and the option of starting therapy for moderate to severe symptoms in women under 60 or within 10 years of onset [19].

The FDA announced its first six approvals in February 2026, covering topical vaginal estrogen, systemic estrogen-alone, estrogen plus progestogen, and progestogen-alone for women with a uterus who use systemic estrogen [9]. Individual labels keep changing.

Many labels have not changed yet. The Premarin oral label effective 4 June 2026 still carries a box titled 'ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA' [10], and the Prempro/Premphase label effective 28 April 2026 still lists cardiovascular disorders, breast cancer, endometrial cancer and probable dementia [11]. Updated labels do exist: Divigel, effective 27 February 2026, now has a box limited to endometrial cancer from unopposed estrogen in women with a uterus, and keeps the cardiovascular, thromboembolic and gallbladder warnings in Warnings and Precautions [18].

Non-hormonal prescription options

Three drugs are FDA-approved for menopausal hot flashes, and they are not interchangeable.

Paroxetine mesylate 7.5 mg (Brisdelle), approved in 2013, is taken once daily at bedtime — a lower dose than paroxetine used for depression, and not approved for any psychiatric condition [2]. It carries the SSRI suicidality boxed warning, and the label lists contraindications including MAOI use (and within 14 days), thioridazine, pimozide and pregnancy [2]. Paroxetine is a strong CYP2D6 inhibitor that lowers levels of tamoxifen's active metabolite, and the label says to consider avoiding concomitant use with tamoxifen [2].

Fezolinetant (Veozah), approved in 2023, is a neurokinin 3 receptor antagonist taken as a 45 mg tablet once daily; it is not a hormone [3]. The label requires liver tests before starting, monthly for the first three months, then at 6 and 9 months, with no start if ALT or AST is 2 times the upper limit of normal or more, or total bilirubin is 2 times that limit or more [3]. It is contraindicated with known cirrhosis, severe renal impairment or end-stage renal disease, and with CYP1A2 inhibitors [3]. In pooled trials, transaminases above 3 times the upper limit occurred in 2.3% of women on 45 mg (25 of 1,100) versus 0.9% on placebo (8 of 952) [3]. The FDA added a boxed warning for hepatotoxicity in December 2024, after a September 2024 Drug Safety Communication based on a postmarketing report of a patient with liver-test abnormalities and symptoms after about 40 days of treatment [21]. At week 12, Veozah 45 mg reduced moderate to severe hot flashes by 2.6 more per day than placebo in trial 1 and 2.5 more per day in trial 2 [3].

Elinzanetant (Lynkuet), approved 24 October 2025, is a dual NK1 and NK3 receptor antagonist taken as 120 mg (two 60 mg capsules) at bedtime, and carries no boxed warning [4]. The label requires baseline liver tests and a follow-up at three months, and pregnancy must be excluded before starting because the drug is contraindicated in pregnancy [4]. The label says to avoid strong CYP3A4 inhibitors and grapefruit juice [4]. Nervous-system effects — sleepiness, fatigue, vertigo, dizziness, presyncope — occurred in 11.9% of women on elinzanetant versus 3.5% on placebo across the three OASIS trials [4]. At week 12, Lynkuet reduced moderate to severe hot flashes by 3.22 more per day than placebo in OASIS 1 and 3.24 more per day in OASIS 2 [4].

The Menopause Society's 2023 nonhormone position statement, written before elinzanetant was approved, recommends cognitive-behavioral therapy, clinical hypnosis, SSRIs/SNRIs, gabapentin and fezolinetant at Level I, oxybutynin at Levels I-II, and weight loss and stellate ganglion block at Levels II-III; it does not recommend paced respiration or supplements and herbal remedies [22].

Vaginal symptoms need a different treatment

For bothersome vaginal symptoms not relieved by over-the-counter products, the Menopause Society's 2022 statement recommends low-dose vaginal estrogen, vaginal prasterone or oral ospemifene [1]. Estring is a vaginal estradiol ring [23]. Osphena (ospemifene, approved 2013) and Intrarosa (prasterone vaginal insert, approved 2016) are approved for painful intercourse due to menopause [7][8], and the Premarin label says that when prescribing solely for vaginal symptoms, topical vaginal products should be considered [10].

Vaginal bleeding after menopause is not normal and warrants prompt evaluation [5].

What the Women's Health Initiative actually found

The 2002 estrogen-plus-progestin trial enrolled 16,608 postmenopausal women aged 50 to 79 with a uterus (mean age about 63) and was stopped at a mean of 5.2 years; compared with placebo, conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily carried hazard ratios of 1.29 for coronary heart disease, 1.26 for breast cancer, 1.41 for stroke and 2.13 for pulmonary embolism [24].

Longer follow-up is more reassuring on mortality. Across 27,347 women in both trials with 18-year cumulative follow-up, the all-cause mortality hazard ratio was 0.99 (95% CI 0.94-1.03) pooled, 1.02 with estrogen plus progestin and 0.94 (0.88-1.01) with estrogen alone; cardiovascular and cancer mortality did not differ from placebo [25].

Breast cancer splits by regimen. Over a median cumulative follow-up beyond 20 years, estrogen alone in 10,739 women with a prior hysterectomy was associated with lower breast cancer incidence (hazard ratio 0.78, 95% CI 0.65-0.93) and lower breast cancer mortality (0.60, 0.37-0.97); estrogen plus progestin in 16,608 women was associated with higher incidence (1.28, 1.13-1.45) and a mortality hazard ratio of 1.35 (0.94-1.95), which was not statistically significant [26].

The dementia finding comes from a specific group. In the Women's Health Initiative Memory Study of 4,532 women aged 65 or older, estrogen plus progestin produced a probable dementia hazard ratio of 2.05 (1.21-3.48), or 45 versus 22 cases per 10,000 person-years over about four years; estrogen alone gave 1.49 (0.83-2.66, not significant), and pooled the two trials gave 1.76 [27][28]. The Premarin label states that it is unknown whether this finding applies to younger postmenopausal women [10]. A 2024 review by WHI investigators concludes the trials do not support hormone therapy to prevent cardiovascular disease, dementia or other chronic disease, but do support starting before age 60 for bothersome symptoms [29].

Oral versus transdermal estrogen and clot risk

A UK nested case-control study compared 80,396 women aged 40 to 79 with venous thromboembolism against 391,494 matched controls. Oral hormone therapy carried an adjusted odds ratio of 1.58 (95% CI 1.52-1.64) — 1.40 for estrogen-only and 1.73 for combined preparations. Estradiol carried lower risk than conjugated equine estrogen (0.85 for estrogen-only, 0.83 for combined), the highest risk was conjugated equine estrogen plus medroxyprogesterone acetate at 2.10, and the lowest was estradiol plus dydrogesterone at 1.18 (0.98-1.42). Transdermal preparations were not associated with venous thromboembolism risk [12]. This is observational data, not a randomized comparison.

Does hormone therapy cause weight gain?

A Cochrane review of 22 randomized trials found no significant weight difference between hormone users and non-users: plus 0.66 kg with unopposed estrogen (95% CI -0.62 to 1.93) and minus 0.47 kg with combined therapy (-1.63 to 0.69) [30]. That review searched trials only through August 1998, and the trials were mostly small. In the SWAN body composition study, the rate of fat gain doubled at the start of the transition and lean mass declined, continuing until about two years after the final period; total weight climbed steadily beforehand with no acceleration at the transition and flattened afterward [31]. A 2012 review concluded that weight gain itself cannot be attributed to the transition, though the hormonal change is associated with more total and abdominal fat, and that estrogen therapy may partly prevent that shift [32]. Weight management is not among Premarin's labeled indications [10].

Compounded bioidentical hormones

FDA-approved estradiol and progesterone products contain hormones identical to those the body makes, and the FDA says it has no evidence that compounded bioidentical hormones are safe and effective, recommending FDA-approved hormone therapy instead; there are no FDA-approved estriol drugs [33]. ACOG Clinical Consensus No. 6 (2023) states that compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist, and that patients who request it should be told it lacks FDA approval [34].

What determines the starting point

Four factors drive the choice. The dominant symptom decides the target: hot flashes and night sweats point to systemic therapy, while vaginal dryness and painful intercourse point to local therapy [1][10]. Timing decides the balance of benefits and risks, with the favorable window being under 60 or within 10 years of menopause onset [1]. The uterus decides whether a progestogen is needed [10]. And contraindications decide what is off the table. The Premarin label lists undiagnosed abnormal genital bleeding, breast cancer or a history of it (except selected palliative use), estrogen-dependent neoplasia, active or past deep vein thrombosis or pulmonary embolism, active or past stroke or heart attack, hepatic impairment or disease, protein C, protein S or antithrombin deficiency or another thrombophilia, and known anaphylaxis or angioedema to the product [10].

For menopause before age 40 (premature) or between 40 and 45 (early), a review describes managing these women with hormone replacement at least until the natural age of menopause, to limit long-term bone and cardiovascular effects [35].

Frequently asked questions